Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Public ClinicalTrials.gov record NCT00932646. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Study identification
- NCT ID
- NCT00932646
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- BI 1744 (Olodaterol) Low Dose Drug
- BI 1744 (Olodaterol) Medium Dose Drug
- Placebo Drug
- Foradil Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2009
- Primary completion
- Apr 30, 2010
- Completion
- Not listed
- Last update posted
- Feb 4, 2016
Started 2009
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1222.25.25009 Boehringer Ingelheim Investigational Site | Jasper | Alabama | — | — |
| 1222.25.25002 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1222.25.25003 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 1222.25.25007 Boehringer Ingelheim Investigational Site | Winter Park | Florida | — | — |
| 1222.25.25010 Boehringer Ingelheim Investigational Site | Austell | Georgia | — | — |
| 1222.25.25008 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 1222.25.25012 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 1222.25.25004 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1222.25.25011 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1222.25.25014 Boehringer Ingelheim Investigational Site | Seneca | South Carolina | — | — |
| 1222.25.25006 Boehringer Ingelheim Investigational Site | Knoxville | Tennessee | — | — |
| 1222.25.25005 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1222.25.25013 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00932646, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00932646 live on ClinicalTrials.gov.